Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Episode 20 of "Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Raman Malhotra, MD, on the current state of sleep medicine and what's to come in the near future.
With many patients presenting with an unknown time of last known well, G. Abbas Kharal, MD, MPH; Emmanuel C. Obusez, MD; and M. Shazam Hussain, MD, FRCP(C), FAHA explore establishing a tissue window using advanced imaging techniques may allow for more effective intervention and better outcomes.
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, shared his thoughts on how technology has affected patient care and the patient-physician dynamic during the COVID-19 pandemic.
Plagued by a long history of under- and inadequate treatment, Duren M. Ready, MD, FAHS, and Evelyn Sbar, MD, describe how clinicians now have more options than ever to craft a personalized, effective plan for their patients.
Mark Freedman, MD, highlights the OLKIOS phase 3b study evaluating ofatumumab’s continued efficacy in patients previously treated with traditional anti-CD20 therapy, as well as concerns about switching from a humanized anti-CD20 monoclonal antibody to a fully human monoclonal antibody.